Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Abstract
Dual MAPK pathway inhibition (dMAPKi) with BRAF and MEK inhibitors improves survival in BRAF V600E/K mutant melanoma, but the efficacy of dMAPKi in non-V600 BRAF mutant tumors is poorly understood. We sought to characterize the responsiveness of class II (enhanced kinase activity, dimerization dependent) BRAF mutant melanoma to dMAPKi.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 13, 2018
- Source ID
- 10.1158/1078-0432.ccr-17-3384
Entities
People
- Alexei Protopopov
- April A.n. Rose
- Catalin Mihalcioiu
- Dan Moldoveanu
- Dana Vuzman
- David Hogg
- Ian R. Watson
- Kevin Petrecca
- Maria Lvova
- Marie-christine Guiot
- Mathieu Lajoie
- Matthew Dankner
- Morag Park
- Paul Savage
- Peter M. Siegel
- Shivshankari Rajkumar
- Tan-trieu Nguyen
- Xiu Huang
Organizations
- Canadian Institutes of Health Research
- Harvard Medical School
- McGill University
- Melanoma Research Alliance
- United States Department of Defense
- University of Toronto
- V Foundation for Cancer Research